ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE) | Finanzwire

Basculer en Français

9475	Companies
185441	Keywords
117777	Articles
99294	Press releases

Headlines Articles Press releases ORPHAN SYNERGY EUROPE-PHARMA

Home
Companies
ORPHAN SYNERGY EUROPE-PHARMA

PRESS RELEASE

published on 06/20/2025 at 19:30, 5 months 14 days ago

OSE Immunotherapeutics Reaffirms Commitment to Holding a Transparent and Serene General Meeting in Compliance with Market Rules
OSE Immunotherapeutics reaffirms commitment to transparent and serene General Meeting in compliance with market rules, providing 'Questions and Answers' document for shareholders

Shareholders Transparency General Meeting OSE Immunotherapeutics Market Rules
BRIEF

published on 06/19/2025 at 15:58, 5 months 15 days ago

Strategic change within OSE Immunotherapeutics

Board Of Directors General Meeting Crossing Thresholds OSE Immunotherapeutics Shareholders' Agreement
BRIEF

published on 04/30/2025 at 07:35, 7 months 5 days ago

OSE Immunotherapeutics Presents New Gene Expression Signature at AACR 2025

Immuno-oncology Personalized Treatment Immune Checkpoint Blockade Gene Expression Signature Cancer Prediction
PRESS RELEASE

published on 04/30/2025 at 07:30, 7 months 5 days ago

Immuno-Oncology Results from Research Collaboration with Léon Bérard Cancer Center Presented at AACR Annual Meeting 2025
OSE Immunotherapeutics and Léon Bérard Cancer Center present a new gene expression signature for predicting clinical response to immune checkpoint at AACR Annual Meeting 2025

AACR Annual Meeting OSE Immunotherapeutics Gene Expression Signature Léon Bérard Cancer Center Clinical Response Prediction
BRIEF

published on 04/09/2025 at 07:35, 7 months 26 days ago

OSE Immunotherapeutics to Present Data on Lusvertikimab at DDW 2025

Ulcerative Colitis OSE Immunotherapeutics Lusvertikimab Phase 2 Extension DDW 2025
PRESS RELEASE

published on 04/09/2025 at 07:30, 7 months 26 days ago

OSE Immunotherapeutics to Present Groundbreaking Extension Period Data on Lusvertikimab at DDW 2025
OSE Immunotherapeutics to present new data on Lusvertikimab's long-term benefits and safety in ulcerative colitis at DDW 2025, showcasing potential in autoimmune diseases

Ulcerative Colitis Immuno-oncology Inflammatory Diseases OSE Immunotherapeutics Lusvertikimab
BRIEF

published on 11/04/2024 at 07:35, 1 year 1 month ago

OSE Immunotherapeutics Reveals Promising Phase 2 Results for Ulcerative Colitis Treatment

Ulcerative Colitis Phase 2 Study OSE Immunotherapeutics Clinical Results Lusvertikimab
PRESS RELEASE

published on 11/04/2024 at 07:30, 1 year 1 month ago

OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis
OSE Immunotherapeutics reports positive results from Phase 2 study of Lusvertikimab for Ulcerative Colitis treatment. Primary endpoint met with high clinical and endoscopic remission rates

Positive Results Phase 2 Study OSE Immunotherapeutics Lusvertikimab Ulcerative Colitis Treatment
BRIEF

published on 09/10/2024 at 07:35, 1 year 2 months ago

OSE Immunotherapeutics Launches Phase 3 Study for Tedopi® in Lung Cancer

NSCLC Immunotherapy Phase 3 Trial Cancer Vaccine Global Launch
PRESS RELEASE

published on 09/10/2024 at 07:30, 1 year 2 months ago

OSE Immunotherapeutics Announces Global Launch of Artemia Phase 3 Registration Study for Cancer Vaccine Tedopi® in Second-Line Non-Small Cell Lung Cancer
OSE Immunotherapeutics launches international Phase 3 trial 'Artemia' of cancer vaccine Tedopi® in second-line NSCLC treatment, aiming for regulatory approval in Europe and North America

NSCLC Phase 3 Trial OSE Immunotherapeutics Artemia Tedopi

Accesswire

Published on 12/05/2025 at 02:35, 8 hours 16 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 8 hours 21 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 9 hours 51 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 11 hours 46 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 11 hours 51 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 10:30, 21 minutes ago

Tradegate Exchange and Börse Berlin merge to form Tradegate BSX
Published on 12/05/2025 at 10:15, 36 minutes ago

Wuxi’s Liangxi District: Where 3,000 Years of Jiangnan Culture Thrives
Published on 12/05/2025 at 09:40, 1 hour 11 minutes ago

Chery Partners with 2025 Asian Youth Para Games, Taking Center Stage in Global Sports with Passion and Aspiration
Published on 12/05/2025 at 09:30, 1 hour 21 minutes ago

REPLOID Group AG: Exhibitor at the BIOGAS Convention & Trade Fair in Nuremberg, Germany
Published on 12/05/2025 at 09:05, 1 hour 46 minutes ago

Transforming Football: IBM and Bayer 04 Leverkusen Use AI for Superior Game Analysis

Les Echos

Published on 12/05/2025 at 08:45, 2 hours 6 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 16 hours 51 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 17 hours 6 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 17 hours 7 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day 3 hours ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health

View all LES ECHOS COMFI WIRE